On October 12th we invited Clustermarket to come talk about cloud-based tools for R&D companies. Did you miss the webinar? No worries! Click the button below to watch it back! During his presentation, Clustermarket
London, 27th September 2021 - Kadans Science Partner has added Merlin Place, Cambridge, UK to its Pan-European portfolio. The asset was acquired from a private investor. This acquisition continues Kadans’ growth in Cambridge following
The search for renewable energy sources is gaining ground. Wind and solar energy have been familiar to us for quite some time, but there are countless other innovations that generate emission-free energy. The question
Date: Tuesday, October 12Programme:11.00 AM CEST : Presentation Clustermarket11.45 AM CEST : Q & AWhere: OnlineThis webinar is powered by: Clustermarket When managing an R&D facility, you have many responsibilities in order to have your
Kadans Science Partner welcomes global molecular diagnostics innovator, Sense Biodetection (Sense), to The Science Quadrant at Abingdon Science Park, Oxfordshire. The move doubles Sense’s existing laboratory capacity, enhancing the firm’s capability to accelerate development
Cancer is one of the world’s most devastating diseases. Its treatment can be punishing, and have several nasty side effects. Fortunately, scientists have a better idea now of how to treat it, and the
Online criminaliteit is nu net zo gewoon en voor de hand liggend als in de offline wereld: Ddos-aanvallen, diefstal van persoonsgegevens, phishing... en ga zo maar door. Maar in onze verbonden maatschappij staat er
Building the Future aflevering 5: Jouw volgende arts wordt een robot Als er één gebied is waar technologische ontwikkelingen elkaar in hoog tempo opvolgen, dan is het wel de medische sector. Een groeiend aantal
Louvain-la-Neuve, 3 augustus 2021 - Kadans Science Partner heeft haar portefeuille uitgebreid met de verwerving van Watson & Crick Hill. Hiermee voegt Kadans haar eerste locatie in België toe aan de Europese portefeuille. Watson & Crick
AXA IM Alts has raised €1.9 billion of equity to accelerate investments into the Life Sciences sector. The capital raised will primarily be invested through Kadans Science Partner, which will enable Kadans to execute
